Plain-English translation of NCT07565428 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help improve the negative symptoms of schizophrenia — things like reduced motivation, emotional blunting, or difficulty with social interaction. The study involves two phases: first, a 12-week period where some participants get the medication while others get a placebo (dummy pill), and then a 40-week follow-up to see how well the treatment works and whether people stay stable.
Current treatments for schizophrenia work well for some symptoms but don't always help much with the negative symptoms that make it hard for people to work, socialize, or care for themselves. Researchers hope this medication could fill that gap and help people feel better and function better in daily life.
You likely qualify if…
You likely don't qualify if…
You would take a daily oral medication (or placebo) for 12 weeks, then continue in a second phase for 40 more weeks where you might receive the new medication, a standard antipsychotic, or a placebo depending on which group you're assigned to. You'll have regular visits with the research team to assess how you're doing, answer questions about your symptoms, and monitor for any side effects. Your caregiver or family member will be asked to help track your progress and support your participation throughout the year-long study.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States